Effective treatment of edema and endothelial barrier dysfunction with imatinib

Circulation

Volumn 126, Issue 23, 2012, Pages 2728-2738

  Aman, Jurjan ^a   Van Bezu, Jan ^a   Damanafshan, Amin ^a   Huveneers, Stephan ^b   Eringa, Etto C ^a   Vogel, Steven M ^c   Groeneveld, A B Johan ^d   Noordegraaf, Anton Vonk ^a   Van Hinsbergh, Victor W M ^a   Van Nieuw Amerongen, Geerten P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Abl related gene tyrosine kinase; Edema; Endothelium; Imatinib; Sepsis

Indexed keywords

ABELSON KINASE; HISTAMINE; IMATINIB; RAC1 PROTEIN; SMALL INTERFERING RNA; THROMBIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; EDEMA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

ANIMALS; CAPILLARY PERMEABILITY; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PIPERAZINES; PULMONARY EDEMA; PYRIMIDINES; SKIN; TREATMENT OUTCOME;

EID: 84870608825     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.134304     Document Type: Article

References (33)

1. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med. 2011;3:8825.
2. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Review. 2006;86:279-367.
3. Weis SM, Cheresh DA. Pathophysiological consequences of VEGFinduced vascular permeability. Nature. 2005;437:497-504. (Pubitemid 41613541)
4. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;28:147-163.
5. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk Noordegraaf A. Possible role of imatinib in clinical pulmonary venoocclusive disease. Eur Respir J. 2008;32:232-235.
6. Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2010;184:3-20.
7. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308-1316. (Pubitemid 40385302)
8. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimmiger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821. (Pubitemid 41434408)
9. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, van Etten RA, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-916. (Pubitemid 44175142)
10. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
11. Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, Sangiolo D, Fizzotti M, Caravelli D, Capaldi A, Anselmetti G, Palesandro E, D'Ambrosio L, Coha V, Obert R, Aglietta M, Grignani G. Complete resolution of lifethreatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol. 2011;29:e691-e693.
12. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14:731-737.
13. Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557-561.
14. Lo CM, Keese CR, Giaever I. Cell-substrate contact: another factor may influence transepithelial electrical resistance of cell layers cultured on permeable filters. Exp Cell Res. 1999;250:576-580. (Pubitemid 29367467)
15. Moy AB, Winter M, Kamath A, Blackwell K, Reyes G, Giaever I, Keese C, Shasby DM. Histamine alters endothelial barrier function at cell-cell and cell-matrix sites. Am J Physiol Lung Cell Mol Physiol. 2000;278:L888-L898. (Pubitemid 30351043)
16. Vogel SM, Orrington-Myers J, Broman M, Malik AB. De novo ICAM-1 synthesis in the mouse lung: model of assessment of protein expression in lungs. Am J Physiol Lung Cell Mol Physiol. 2006;291:L496-L501. (Pubitemid 44343727)
17. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nature Protocols. 2009;4:31-36.
18. Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood. 2010;115:2038-2047.
19. Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM. Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem. 2010;285:40201-40211.
20. Ingber DE. Opposing views on tensegrity as a structural framework for understanding cell mechanics. J Appl Physiol. 2000;89:1663-1670.
21. Birukova AA, Alekseeva E, Cokic I, Turner CE, Birukov KG. Cross talk between paxillin and Rac is critical for mediation of barrier-protective effects by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol. 2008;295:L593-L602.
22. Raven K. Rodent models of sepsis found shockingly lacking. Nat Med. 2012;18:998.
23. Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009;65:545-549.
24. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141-3147.
25. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs. 2009;27:31-40.
26. Shikata Y, Birukov KG, Garcia JG. S1P induces FA remodeling in human pulmonary endothelial cells: role of Rac, GIT1, FAK, and paxillin. J Appl Physiol. 2003;94:1193-1203. (Pubitemid 36232038)
27. Peacock JG, Miller AL, Bradley WD, Rodriguez OC, Webb DJ, Koleske AJ. The Abl-related gene tyrosine kinase acts through p190RhoGAP to inhibit actomyosin contractility and regulate focal adhesion dynamics upon adhesion to fibronectin. Mol Biol Cell. 2007;18:3860-3872. (Pubitemid 47519479)
28. Peacock JG, Couch BA, Koleske AJ. The Abl and Arg non-receptor tyrosine kinases regulate different zones of stress fiber, focal adhesion, and contractile network localization in spreading fibroblasts. Cytoskeleton (Hoboken). 2010;67:666-675.
29. Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood. 2011;117:1751-1760.
30. Li R, Pendergast AM. Arg kinase regulates epithelial cell polarity by targeting beta1-integrin and small GTPase pathways. Curr Biol. 2011;21:1534-1542.
31. Bradley WD, Koleske AJ. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci. 2009;122:3441-3454.
32. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res. 2010;180:103-114.
33. Dudek SM, Chiang ET, Camp SM, Guo Y, Zhao J, Brown ME, Singleton PA, Wang L, Desai A, Arce FT, Lal R, Van Eyk JE, Imam SZ, Garcia JG. Abl tyrosine kinase phosphorylates nonmuscle myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell. 2010;21:4042-4056.